The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 79 | 0.0x | 20.8x | Top tier | |
Growth | 41 | -74.1% | 6.1% | Around median | |
Quality | 5 | -252.9% | 6.6% | Bottom tier | |
Safety | 25 | — | 0.7x | Bottom tier | |
Capital Return | 1 | — | 2.02% | Bottom tier | |
Momentum | 9 | -100.0% | 4.1% | Bottom tier | |
Sentiment | 94 | — | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Aditxt, Inc. (listed on NASDAQ under the symbol ADTX) is a life sciences company focused on developing and commercializing technologies focused on improving and modulating the immune system. The company aims to provide innovative solutions for monitoring immune health and reprogramming it to address various diseases, generating revenue through its life sciences platforms and associated diagnostic and therapeutic products and services.
Looking at the recent quarterly financial results for the first quarter of 2026 (Q1 2026), the company recorded revenue of $12,159, with a gross profit of $2,868. However, the company continues to face significant operational challenges, as net income was a loss of -$15.9 million, and earnings per share (EPS) was negative at -$790.49, reflecting ongoing financial pressure on its business model despite revenue growth compared to the fourth quarter of 2025, which recorded revenue of $3,195 and a net loss of -$43.1 million.
Aditxt, Inc. (ADTX) stock has an analyst consensus recommendation of Buy, with an estimated average price target of $1,280, which is the same value for both the high and low estimates. The stock is currently trading at levels far below this suggested price target, while the price-to-earnings (P/E) ratio remains unavailable due to the company's continued accumulation of net losses totaling -$49.9 million on a trailing twelve-month (TTM) basis.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
During the first quarter of 2026, Aditxt achieved revenue of $12,159, representing a significant jump compared to fourth-quarter 2025 revenue of $3,195. The company also recorded a gross profit of $2,868 in the same quarter, compared to a meager gross profit of $268 in the previous quarter. Despite this operational growth in revenue, the company continues to record significant net losses that affect its overall profitability.
Aditxt appointed Jeffrey Bush as interim CEO of the company on June 6, 2026. This strategic appointment aims to strengthen and develop the company's life sciences platform and drive commercial growth. Through this leadership step, the company hopes to improve its financial and operational performance and reduce the accumulated losses it suffered in previous periods.
Aditxt ended fiscal year 2025 (FY 2025) with total revenue of only $3,195 and a modest gross profit of $268. On the profitability front, the company recorded a massive annual net loss of -$43.1 million, resulting in a negative earnings per share (EPS) of -$1,153.83. These figures illustrate the scale of the structural financial challenges the company faced before entering the first quarter of 2026.
Automated analysis for informational purposes only — not investment advice.
Aditxt (ADTX) stock has an analyst consensus recommending Buy, with an average price target set at $1,280 per share. This target matches both the high and low estimates provided by analysts, indicating agreement on the target value. The stock is currently trading at levels far below this target, reflecting a significant gap and optimistic analyst expectations compared to the company's current financial performance.
Insider activity data for Aditxt indicates a generally neutral signal, with net purchases of 37,632.88 recorded over the past three months. During this period, 4 purchases were recorded against 7 sales by company insiders. The latest recorded insider transaction dates back to June 11, 2026, reflecting ongoing interest and active trading by company insiders.